Research highlights vaccines against bacterial sexually transmitted infections, indicating potential public health benefits despite challenges like antimicrobial resistance and inequitable diagnostics
Asymptomatic transmission, inequitable access to diagnostics, and rising antimicrobial resistance are major barriers to controlling the bacterial sexually transmitted infections (STIs) gonorrhea, chlamydia, and syphilis. Developing vaccines against these infections has therefore become a key STI research priority, requiring innovative research, expedited clinical development, and increased investment.
No takes yet. Share an insight, caveat, or question.
Gottlieb et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: